online ISSN 2415-3176
print ISSN 1609-6371
logoExperimental and Clinical Physiology and Biochemistry
  • 16 of 16
Up
ECPB 2015, 71(3): 98–104
https://doi.org/10.25040/ecpb2015.03.098
Literature review

Modern anabolic agents and prospects thiazolidоne derivatives as a new class

KOROPETSKA N.
Abstract

Anabolic means accelerating the update and the formation of structural parts of cells and tissues mainly due to regeneration and stimulation of protein synthesis.

The aim of the study was a review of scientific literature sources on modern approaches to the modulation of anabolic pharmacology and prospects thiazolidine derivatives as their new class.

Analysis of the literature found term use for research and development of anabolic agents, despite their androgenic effects on the human body. The problem of finding a universal anabolic activity with maximum and minimum androgenic action remains open and timely.

The spectrum of therapeutic use of anabolic drugs at a broad-cachexia, infectious diseases, muscular dystrophy, burns, injuries, fractures, atrophy, cancer and other diseases. Despite the enormous potential pharmacological anabolic drugs, the key problem is the issue of side effects with prolonged use them.

Considering the negative side effects and social aspects of the use of drugs and hormones anabolic steroids considerable attention pharmacological science focused search and create an anabolic drugs nonsteroidal structure with equivalent effect parameters improved bioavailability and toxicity. It should be noted also very costly process for anabolic steroid drugs because of the special uniqueness of their chemical structure. At the same time, a clear direct effect on myocardial processes or osteoanabolizmu these drugs do not show.

A possible way to find new anabolic agents is to study molecular structures and functions of known nuclear receptors and ligands specific search for them. These ligands are derived classic 4-tiazolidynonu that exhibit antibacterial, antifungal, anti-inflammatory, antitumor, antiviral and antioxidant effects.

Noting survey work, it can be argued that the modulation of androgen (nuclear) receptor is a key strategy impact on anabolism pharmacological agents, including derivatives 4 tiazolinynonu who possess a high level of anabolic activity and bioavailability satisfactory parameters.

An important aspect of the pharmacological effects of 4-tiazolidynonu compounds are characterized by distinct antioxidant effect, which is often combined with the main activity, and often antioxidant effect is desirable and necessary for cellular anabolism. Another no less important medical and social problem is the alimentary dystrophy, which are more characteristic of the population of the Third World and also require therapeutic correction aimed at anabolism. Against the background of such a gigantic need for effective anabolic preparations number of scientific – practical research and development on this subject is extremely small. Over the past 25 years (from 1989 to 2014) in "Pharmacologicalreviews" published only two fundamental literary reviews, which are indirectly deal with these research and development of anabolic drugs and are devoted to studying the properties and pharmacological potential nuclear (nuclear) receptors and their synthetic ligands.

Modern high-performance and highly anabolic drugs are relevant and necessary to medicine. Significant prospects for the discovery of new compounds with high anabolic activity and satisfactory bioavailability parameters opens in-depth screening of 4-tiazolidynon.

Keywords: anabolism, thiazolidоne, retabolil, testosterone propionate

Full text: PDF (Ukr) 0.99M

References
  1. 1. Golovenko N. Kontury of the future farmakolohyy. Pharmacology and drug toxicology. 2013;6:81-85.
  2. 2. Ed. Bogatyryova R, Bogachev R, Moskalenko V el al. State Form drugs. Issue fifth [electronic resource]. Kyiv; 2013:764-766.
  3. 3. Zamyatnyn A. Frahmentomyka pryrodnyh peptydnyh structures. Successes byolohycheskoy chemistry. 2009;49:405-428.
  4. 4. Zelisko N, Atamanyuk D, Lesyk R. The synthesis of new derivatives tiopirano [2,3-d] -tiazoliv from itaconic acid as potential biologically active compounds. J. org. and pharm. Himiyi. 2010;8(2):69-73.
  5. 5. Zimenkovsky B, Lesyk R. 4-Tiazolidynony and related heterocyclic system. Hovi areas of pharmaceutical research, Organic and Bioorganic Chemistry of the Lviv National Medical University Daniel Galician. Clinical Pharmacy, Pharmacotherapy and Medical Standardization. 2010;3-4:4-30.
  6. 6. Zimenkovsky B, Lesyk R. 4 thiazolidones. Chemistry, physiological performance and prospects. Monograph. Vinnycia: A NEW BOOK; 2004. 106. ISBN 966-8609-10-7.
  7. 7. Koropetskа N, Ostapiv D, Nyektyehayev I et.al. Comparative analysis of the impact retabolil, derived tiopiranotiazolu (substance LES-2222), testosterone propionate on protein metabolism in the body of rats food deprivation. Experimental and Clinical Physiology and biohimiya. 2015;2:56-62.
  8. 8. Lesyk R. Synthesis and biological activity of condensed and noncondensable heterocyclic systems based on 4 azolidoniv: Author. Thesis. for obtaining sciences. Degree of Dr. farm. Sciences: 15.00.02 "Pharmaceutical Chemistry and Pharmacognosy". Lviv. 2005. 39.
  9. 9. Novikov L, Faletrov Y, Kovalev E et al. That structure and function of enzymes for byosynteza steroydov join the new genetic technologies. Successes byolohycheskoy chemistry. 2009;49:159-210.
  10. 10. Povorozniuk V, Dzerovych N, Hans D. Effect on Quality antyosteoporotycheskyh funds kostnoy fabric: review of literature and Results of research sobstvennyh. Ukrainian Journal of Rheumatology. 2013;3:47-50.
  11. 12. Poshyvak O, Piniazhko O, Lesyk R et al. The influence of new thiazolidine derivatives to specific parts of the immune system of the rat. Pharmacology and pharmaceutical toksykolohiya. 2008;5-6:74-77.
  12. 13. Tkachenko E, Lesyk R, Lukyanchuk V. Farmakolohycheskaya characteristics and klynycheskoe application proyzvodnyh tyazolydyna. Ukrainian medical almanah. 2005;8(1):214-218.
  13. 14. Chekman Y, Belenychev Y, Horchakova N, Kucherenko L, Buktiyarova N, Pogotova G et al. Antyoksydanty: clinical and pharmacological aspects. Eng. Med. Chasopys. 2014;1:22-28.
  14. 15. Shepelkevych A, DydyshkoY. Sarkopenyya how assotsyyrovannoe status. ARS MEDICA. 2012;15:81-94.
  15. 16. Atamanyuk D, Lesyk R. Search of novel potentialleads among thiopyrano[2,3-d]thiazol-2-one derivatives with pharmacological importance. Bridges in Life Sciences Annual Scientific Review. Pecs. 2007;1(1):43.
  16. 17. Bossola M, Pacelli F, Doglietto G. Novel treatments for cancer cachexia. Expert Opin. Investig. Drugs. 2007;16:1241-1253.
  17. 18. Burris T, Solt A, Wang Y, Crumbley C, Banerjee S, Griffet K et al. Nuclear Receptors and Their Selective Pharmacologic Modulators. Pharmacological Reviews. 2013;65:710-778. doi.org/10.1124/pr.112.006833
  18. 19. Cruz-Jentoft A, Baeyen J, Baueret J, Boirie Y, Cederholm T, Landi F et al. Sarcopenia: European consensus on definition and diagnosis. Report of the European Working Group on Sarcopenia in Older People. Age and Ageing. 2010;39:412-423. doi.org/10.1093/ageing/afq034
  19. 20. Dodge T, Hoagland M. The use of anabolic androgenic steroids and polypharmacy: A review of the literature. Drug and Alcohol Dependence. 2011;114:100-109. doi.org/10.1016/j.drugalcdep.2010.11.011
  20. 21. Ebner N, teinbeck L, Doehner W, Anker S, Haehling S. Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies. J. Cachexia Sarcopenia Muscle. 2014;5:27-34. doi.org/10.1007/s13539-014-0136-z
  21. 22. Gao W, Kim J, Dalton J. Pharmacokinetics and Pharmacodynamics of Nonsteroidal Androgen Receptor Ligands. Pharmaceutical Research. 2006;23:1641-1658. doi.org/10.1007/s11095-006-9024-3
  22. 23. Jones A, Chen J, Hwang D et al. Preclinical Characterization of a (S)-N-(4-Cyano-3-Trifluoromethyl-Phenyl)-3-(3-Fluoro,4-Chlorophenoxy)-2-Hydroxy-2-Methyl-Propanamide: A Selective Androgen Receptor Modulator for Hormonal Male Contraception. Endocrinology. 2009;150:385-395. doi.org/10.1210/en.2008-0674
  23. 24. Kanayama G, Amiaz R, Seidman S, Pope H. Testosterone supplementation for depressed men: current research and suggested treatment guidelines. Exp. Clin. Psychopharmacol. 2007;15:529-538.
  24. 25. Kicman A. Pharmacology of anabolic steroids. British Journal of Pharmacology. 2008;154:502-521. doi.org/10.1038/bjp.2008.165
  25. 26. Kryshchyshyn A, Atamanyuk D, Lesyk R. Fused Thiopyrano[2,3-d]thiazole Derivatives as Potential Anticancer Agents. Sci. Pharm. 2012;80:509-529.
  26. 27. Lesyk R, Zimenkovsky B, Kaminskyy D, Khyluk D. Thiazolidinone motif in anticancer drug discovery. Experience of DH LNMU medicinal chemistry scientific group. Biopolym. Cell. 2011;2:107-117.
  27. 28. Lynch G, Ryall J. Role of β-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease. Physiol. Rev. 2008;88:729-767.
  28. 29. McCabea S, Brower K, West B, Nelson T, Wechsler H. Trends in non-medical use of anabolic steroids by U.S. college students: Results from four national surveys. Drug and Alcohol Dependence. 2007;90:243-0251. doi.org/10.1016/j.drugalcdep.2007.04.004
  29. 30. Michalik L, Auwerx J, Berger P, Chatterjee V, Glass C, Gonzalez F et al. International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors. Pharmacological Reviews. 2006;58:726-741. doi.org/10.1124/pr.58.4.5
  30. 31. Poole K, Compston J. Osteoporosis and its management. BMJ. 2006;16:1251-1256. doi.org/10.1136/bmj.39050.597350.47
  31. 32. Pötsch M, Tschirner A, Palus S, von Haehling S, Doehner W, Beadle J et al. The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J. Cachexia Sarcopenia Muscle. 2014;5:149-158. doi.org/10.1007/s13539-013-0125-7
  32. 33. Thevis M, Schänzer W. Synthetic anabolic agents: steroids and nonsteroidal selective androgen receptor modulators. Handb. Exp. Pharmacol. 2010;195:99-126.
  33. 34. Thieme D. Doping in Sports. Handbook of Experimental Pharmacology. Berlin, Heidelberg: Springer-Verlag ; 2010. 195. 540.
  34. 35. Tóth M. Myoanabolic steroids and selective androgen receptor modulators: mechanism of action and perspectives . Orvosi Hetilap. 2009;150:2051-2059. doi.org/10.1556/OH.2009.28739
  35. 36. Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management. J. Neurol. Neurosurg. Psychiatry. 2010;81:358-367.
  36. 37. Vajda E, Hogue A, Griffiths K, Meglasson M. Combination Treatment With a Selective Androgen Receptor Modulator (SARM) and a Bisphosphonate Has Additive Effects in Osteopenic Female Rats. Journal of Bone and Mineral Research. 2009;24:231-240. doi.org/10.1359/jbmr.081007
  37. 38. Verma A, Saraf S. 4-Thiazolidinone: a biologically active scaffold. Eur. J. Med. Chem. 2008;43:897-905l.
  38. 39. Verster J, Brady K, Galanter M et al. Anabolic–Androgenic Steroids. Drug Abuse and Addiction in Medical Illness: Causes, Consequences and Treatment–Heidelberg: Springer Science & Business Media Berlin 2012. (ISBN 978-1-4614-3375-0). 251-264.
  39. 40. Visser M. Towards a definition ofsarcopenia – results from epidemiologic studies. The Journal of Nutrition, Health & Aging. 2009;13:713-716. doi.org/10.1007/s12603-009-0202-y
  40. 41. Volynets G, Bdzhola V, Golub A, Synyugin A, Chekanov M, Kukharenko O et al. Rational design of apoptosis signal-regulating kinase 1 inhibitors: Discovering novel structural scaffold. European Journal of Medicinal Chemistry. 2013;61:104-115. doi.org/10.1016/j.ejmech.2012.09.022
  41. 42. Von Haehling S, Lainscak M, Springer J, Anker S. Cardiac cachexia: A systematic overview. Pharmacology & Therapeutics. 2009;121:227-252. doi.org/10.1016/j.pharmthera.2008.09.009
  42. 43. Wagner K, Wagner N. Peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) acts as regulator of metabolism linked to multiple cellular functions. Pharmacology & Therapeutics. 2010;125:423-435. doi.org/10.1016/j.pharmthera.2009.12.001


Програмування - Roman.im